Rodney P. Rocconi - Concepedia

Author

Rodney P. Rocconi

Also Known As

R P Rocconi, R ROCCONI, R Rocconi, R. P. Rocconi, R. Rocconi, R.P. ROCCONI, R.P. Rocconi, RODNEY P. ROCCONI, Rodney P. Rocconi, Rodney P Rocconi

253

Publications

4.1K

Citations

H-Index

101

Concepts

All Affiliations

University of South Alabama University of Alabama at Birmingham USA Mitchell Cancer Institute Gradalis (United States)Gynecologic Oncology Group

About

Rodney P. Rocconi is an author at University of South Alabama specializing in medicine, oncology, and obstetrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	49	2.3K
2	Public Health	9	9	370
3	Health Sciences	4	4	470
4	Engineering	2	2	43
5	Natural Sciences	1	1	11

Rodney P. Rocconi

Publications

3.5K

Citations

H-Index

Page 1

	Year	Citations
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma Mariam A. Stoff‐Khalili, Ángel A. Rivera, J. Michael Mathis, Breast Cancer Research and Treatment Regenerative MedicineMesenchymal Stem CellsCell-based Drug DeliveryTargeted DeliveryMedicine	2007	205
ALDH1A1 Maintains Ovarian Cancer Stem Cell-Like Properties by Altered Regulation of Cell Cycle Checkpoint and DNA Repair Network Signaling Erhong Meng, Aparna Mitra, Kaushlendra Tripathi, PLoS ONE	2014	169
CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival Erhong Meng, B.J. Long, Paula A. Sullivan, Clinical & Experimental Metastasis Stem Cell BiologyMedicineCancer Cell BiologyStem Cell ResearchCancer Biology	2012	165
A Prospective Blinded Evaluation of the Accuracy of Frozen Section for the Surgical Management of Endometrial Cancer Ashley S. Case, Rodney P. Rocconi, J. Michael Straughn, Obstetrics and Gynecology	2006	159
The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma T. Michael Numnum, Rodney P. Rocconi, Jenny M. Whitworth, Gynecologic Oncology Symptomatic AscitesOncologyRefractory Ovarian CarcinomaCancer ManagementPathology	2006	125
Impact of Travel Time on Health Care Costs and Resource Use by Phase of Care for Older Patients With Cancer Gabrielle B. Rocque, Courtney Williams, Harold D. Miller, Journal of Clinical Oncology	2019	112
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande, The Lancet Oncology MedicineImmunologyGynecologyImmune Checkpoint InhibitorCancer Treatment	2020	112
Validation of a venous thromboembolism risk assessment model in gynecologic oncology William Stroud, Jenny M. Whitworth, Margaret Miklic, Gynecologic Oncology ThrombosisPulmonary EmbolismVenous DiseaseVenous ThrombosisMedicine	2014	107
Minority participation in Gynecologic Oncology Group (GOG) Studies Jennifer Scalici, Michael A. Finan, Jennifer Black, Gynecologic Oncology MedicineGynecologyHealth DisparitiesHealth EquityOncology	2015	95
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study Gottfried E. Konecny, Neil J. Finkler, Agustin A. García, The Lancet Oncology MedicineSecond-line DovitinibGynecologyMetastatic Endometrial CancerCancer Treatment	2015	86

Page 1